Circulating insulin-like growth factor 1 (IGF-1) may be directly associated with colorectal cancer risk, and IGF binding protein 3 (IGFBP-3) is one of the most abundantly expressed binding proteins in various cancers. Calcium intakes, primarily from food, have been directly associated with circulating IGF-1, but whether supplemental calcium affects IGF-1 and IGFBP-3 is unknown. We tested the effects of 1.0 and 2.0 g of supplemental elemental calcium daily on circulating IGF-1 and IGFBP-3 concentrations in colorectal adenoma patients in a randomized, double-blinded, placebo-controlled clinical trial (n = 193). IGF-1 and IGFBP-3 were quantified using enzyme-linked immunoassay and quantitative Western ligand blot, respectively. We also assessed cross-sectional associations of these biomarkers with participants' baseline characteristics. We found no appreciable effect of calcium relative to placebo on circulating IGF-1, IGFBP-3, or the IGF-1:IGFBP-3 molar ratio. Mean IGF-1 concentrations were 11.1% higher in those with greater milk intakes (P = 0.05). Mean IGF-1 and IGFBP-3 concentrations were, respectively, 18.0% (P = 0.003) and 16.5% (P = 0.01) higher in men and were monotonically lower with increasing age (both P = 0.01). IGFBP-3 was 17.7% higher among those with higher relative to no alcohol consumption (P = 0.04). While these results support previous findings that IGF-1 concentrations are higher with greater milk intakes, and IGF-1 and IGFBP-3 concentrations differ according to sex and age, they provide no evidence to suggest that supplemental calcium appreciably affects circulating IGF-1, IGFBP-3, or the IGF-1:IGFBP-3 molar ratio in sporadic colorectal adenoma patients.
may potentially act as a potent mitogen, anti-apoptotic peptide, and promoter of angiogenesis when overexpressed. 5 Circulating IGF-1 is predominantly bound to insulin-like growth factor binding protein 3 (IGFBP-3) to increase stability and regulate distribution to tissues. 6 There is no consistent evidence that IGFBP-3 levels are associated with risk of colorectal cancer but may be an indicator of bioavailable IGF-1.
Colorectal cancer is the second leading cause of cancer deaths among men and women combined in the United States. 7 Calcium has been consistently associated with lower risk of colorectal neoplasms, [8] [9] [10] [11] and supplemental calcium reduced sporadic colorectal adenoma recurrence in two 12, 13 of three [12] [13] [14] large randomized controlled trials. The hypothesized mechanisms of calcium's antineoplastic action are through its binding of secondary bile acids and free fatty acids in the colon, which reduces epithelial cell exposure to their damaging effects, 15, 16 and by directly inhibiting proliferation and inducing differentiation of colonic epithelial cells. 17, 18 Milk products are a common source of dietary calcium in the average American diet, and tend to be inversely associated with risk of colorectal cancer, similar to calcium. 8, 19 However, clinical trials suggest that milk product consumption may increase circulating IGF-1 levels, and cross-sectional studies reported positive associations of milk consumption with IGF-1 concentrations. 20, 21 This may be attributable to higher levels of IGF-1 measured in milk produced from cows administered bovine somatotropin (bST) hormone (the most commonly consumed milk in the United States), in comparison to bST-free or organically produced milks. 22 However, calcium may also be obtained from supplemental sources, and to our knowledge, whether supplemental calcium affects circulating IGF-1 and IGFBP-3 concentrations is unknown, and no clinical trial tested
this. Thus, we tested the effects of 1.0 and 2.0 g of supplemental elemental calcium on IGF-1 and IGFBP-3 concentrations in colorectal adenoma patients in a randomized, double-blinded, placebo-controlled trial.
| MATERIALS AND METHODS

| Participant population
For this investigation, we used data and stored blood samples from a randomized, double-blinded, placebo-controlled, three-arm, parallelgroup clinical trial of calcium supplementation conducted in Minneapolis-St. Paul, Minnesota from 1990 to 1993. The recruitment methods and study protocol of this trial were previously described. 23, 24 Briefly, patients 30-74 years of age with a history of a pathology confirmed colorectal adenomatous polyp within the previous 5 years were recruited from a large, private gastroenterology practice. Eligible participants were in good health and must have consumed a western-style diet that included meat and no more than 1100 mg of calcium daily. Additional exclusion criteria included current use of calcium supplements; contraindications to calcium supplementation or rectal biopsies; clinical conditions, dietary habits, or medication that would otherwise affect safety, adherence, or interpretation of the study results; or less than 80% adherence to study pill-taking in a 4-week placebo run-in trial.
| Clinical trial protocol
As previously described, 23 of the patients who were invited for an eligibility visit and subsequently completed the placebo run-trial, 193
were randomized. Participants underwent a baseline visit and were randomly assigned to one of three treatments groups: a placebo control group (n = 66) and 1.0 g (n = 64) and 2.0 g (n = 63) elemental calcium supplementation groups. Randomized group assignment was blinded to all participants, study personnel, and laboratory staff. The calcium carbonate and placebo tablets (prepared by SmithKline
Beecham, Pittsburgh, PA) were administered twice daily with meals, and all pills were identical in size, appearance, and taste.
Medical history, medication use, and information on demographic, dietary, and lifestyle factors were collected at the eligibility and baseline visits via self-administered questionnaires. Usual dietary intakes over the previous 12 months were collected using a 153-item
Willett semi-quantitative food-frequency questionnaire (FFQ). The treatment period was 6 months with follow-up visits at 1, 2, 4, and 6 months. Participants were instructed to follow their usual diets, and pill-taking adherence was assessed at each follow-up visit by interview, questionnaire, and pill count. Non-fasting venous blood samples were collected only at the baseline and 4-month follow-up visits.
Participants were comfortably seated in a chair for 5 min with both feet on the floor before venipuncture. Blood was drawn into pre- batches than the samples to which they were paired; for these duplicate pairs, the CVs for IGF-1 and IGFBP-3 were 14.7% and 22.7%, respectively.
IGFBP-2 concentrations were below the limit of detection in 39 samples;
the CVs for low and high quality control IGFBP-2 samples were 21.4% and 6.7%, respectively; and the CV for the duplicate pairs was 53%. Based on the large number of samples with values below the lower limit of detection and the large CV for the duplicate pairs, we excluded IGFBP-2 from subsequent data analyses.
The analytical range of IGFBP-3, defined by the highest and lowest concentration of recombinant standard used, was 159-10 000 ng/mL.
The lower limit of quantification was 962.37 ng/mL for IGFBP-3, and the analytical sensitivity for IGF-1 was 0.09 ng/mL.
| Statistical analysis
Baseline characteristics of the treatment groups were compared using chi-square or Fisher's exact tests for categorical variables and analysis of variance (ANOVA) for continuous variables.
Of the initial 193 participants, blood samples for measurement of growth factors were available for 189 participants at baseline and 175 at follow-up. Primary analysis was based on the original treatment group assignment at randomization, regardless of adherence (intent-to-treat).
IGF-1 and IGFBP-3 values were log-transformed before statistical testing to improve normality. Mean growth factor parameters were calculated for each treatment group at baseline and 4 month follow-up.
The molar ratio of IGF-1 to IGFBP-3 was calculated prior to logtransformation using the mass to molar conversion of 1 ng/mL IGF-1 = 0.130 nM for IGF-1 and 1 ng/mL IGFBP-3 = 0.036 nM IGFBP-3.
Treatment effects were estimated using a repeated-measures mixed linear model implemented using SAS Institute's Mixed Procedure (PROC MIXED) (SAS version 9.4 software; SAS Institute Inc., Cary, NC). The model included visit, treatment groups, and a treatment group by visit interaction term. Because the growth factor values were natural log transformed, the visit-and treatment-specific geometric means, and the relative treatment effects, defined as (treatment group follow-up mean/treatment group baseline mean)/ (placebo follow-up mean/placebo baseline mean), were obtained directly from the Mixed model output. We also manually calculated the absolute treatment effect, defined as the "difference of differences," or (treatment group follow-up mean-treatment group baseline mean)-(placebo follow-up mean-placebo baseline mean), using the geometric means for each treatment group.
We also conducted a cross-sectional analysis using multivariableadjusted generalized linear models to investigate whether baseline concentrations of IGF-1 and IGFBP-3 were associated with sex, age, body mass index (BMI), regular use of nonsteroidal anti-inflammatory drugs (NSAIDs) or aspirin, alcohol consumption, total energy intake, total fat intake, calcium intake, and red or processed meat consumption. Additionally, associations with milk product intakes were of particular interest, especially the non-calcium (and non-fat) component of milk, which contains IGF-1 as discussed above. To estimate the latter, we used residuals from linear regression models of total dairy and non-fat milk (as the dependent variables) with dietary calcium intake (as the independent variable). This method was modeled after the energy adjustment residual method. 25 Multivariate models were adjusted for sex, age, BMI, total energy intake, and supplemental and dietary calcium as appropriate.
A two-sided P value of <0.05 or a 95% confidence interval that does not include 1.00 was considered statistically significant.
All statistical analyses were performed using SAS version 9.4 software.
| RESULTS
At baseline, the mean age of the 193 study participants was 59 years, 63% were men, and 99% were white. Participants also consumed, on average, 800 mg of dietary calcium and 2.2 servings of dairy products daily. The treatment groups did not differ significantly on demographic, lifestyle, or dietary characteristics (Table 1 ). Adherence to follow-up visit attendance averaged 95.3% and did not differ among treatment groups. In each group, more than 98% of participants took 80% or more of their pills, and the mean percentage of pills taken was 97%.
The mean concentrations of IGF-1, IGFBP-3, and the IGF-1:
IGFBP-3 molar ratio did not differ among treatment groups (Table 2 ).
There were no appreciable effects of either 1 or 2 g calcium supplementation on any of the growth factor concentrations. We also stratified by age, sex, BMI, NSAID or aspirin use, smoking status, alcohol use, physical activity level, total energy intake, and dietary calcium intake, but the estimated treatment effects were similarly null across the strata (data not shown).
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To gain potential insight into whether the null treatment effects were valid or possibly due to the effects of long-term storage on the blood samples, we analyzed baseline associations of participant characteristics with IGF-1, IGFBP-3, and the IGF-1:IGFBP-3 molar ratio (Table 3) . IGF-1 and IGFBP-3 concentrations were 14.9%
(P = 0.02) and 16.5% (P = 0.01) higher in men, respectively, and both were lower with increasing age (P = 0.02 and P = 0.01, respectively).
IGF-1 concentrations were also 11.1% higher among participants in the higher total milk category (P = 0.05), but only an estimated 6.1%
higher in the upper relative to the lower tertile of non-fat milk residuals (P = 0.39). IGFBP-3 concentrations were 17.7% higher among participants consuming seven or more alcoholic drinks per week compared to those consuming none (P = 0.04); however, concentrations were not higher among those with moderate consumption.
IGFBP-3 concentrations were also 13.0% lower in the upper tertile of total milk product residuals (P = 0.04), and IGF-1 was 7.3% lower in the upper relative to the lower tertile of total milk product residuals (P = 0.28). therefore, the significance of this finding is unclear.
There is consistent, though limited, evidence that milk consumption may increase circulating IGF-1 levels. In a clinical trial conducted in adult men and women, there was a statistically significant increase in IGF-1 concentrations among those consuming three servings of nonfat or low-fat milk daily for 12 weeks compared to those not consuming milk. 31 Positive associations of milk consumption and IGF-1 concentrations were also reported in observational studies, 21, [32] [33] [34] [35] though associations of milk consumption with IGFBP-3 levels were primarily null. The findings across the few studies that reported an association of milk consumption with the IGF-1:IGFBP-3 molar ratio were inconsistent. 32, 35, 36 In our study, we examined the milk product Models for all variables except sex adjusted for sex (M/F). Models for all variables except age adjusted for age (continuous). Models for all variables except BMI adjusted for BMI (continuous). Models for dietary variables also adjusted for total energy intake (continuous). Models for total milk products and total milk also adjusted for supplemental calcium (continuous). Models for milk product residuals and non-fat milk residuals also adjusted for dietary calcium (continuous). b Low/high categories determined using sex-specific medians. BMI categories determined using World Health Organization classification of adult normal weight, overweight, and obesity.
been produced using bovine somatotropin hormone, which was approved for use by the Food and Drug Administration in 1993 37 and is hypothesized to increase levels of IGF-1 in milk products. Thus, this is a potential reason why our estimate of IGF-1 from milk products, as estimated by both total milk product and non-fat milk residuals, was not positively associated with circulating IGF-1 levels.
Our findings of differences in IGF-1 and IGFBP-3 concentrations according to sex and age are consistent with those from some, but not all, observational studies. Our observed inverse association of IGF-1 and IGFBP-3 concentrations with age is consistent with previous studies, 33, 35, [38] [39] [40] and lower concentrations of IGF-1 were consistently reported in women. 35, 36, 38 However, the association of IGFBP-3 levels with sex is inconsistent among these studies. Our findings also suggest that IGFBP-3 levels may be positively associated with alcohol consumption. In an 8-week crossover trial among postmenopausal women (n = 53), IGFBP-3 concentrations increased with consumption of one but not two alcohol drinks daily. 41 However, the association is unclear as limited observational studies reported inconsistent associations of IGFBP-3 concentrations with alcohol consumption. 34, 42 To our knowledge, this is the first report on the effect of calcium supplementation on circulating levels of IGF-1 and IGFBP-3 among adenoma patients, and a strength of the study was the randomized, double-blind, controlled, dose-response design. However, there were also several limitations in this study. First, the blood samples collected at the baseline and follow-up visits were non-fasting samples. It is possible that circulating IGF-1 levels may be influenced by dietary sources of IGF-1, which are primarily animal products. Additionally, the time of day at which blood is collected may affect levels of IGF-1 and IGFBP-3. 43 Therefore, in future studies, it may be important to collect 
